KAIROS PHARMA LTD
KAPANYSE AMERICANTrading Snapshot
- Day Range
- $0.36 – $0.36
- 52-Week Range
- $0.27 – $2.11
- Volume
- $2.56B
- Avg Volume
- $2.81B
- Shares Outstanding
- 21.4M
- Next Earnings
- Oct 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $404,254
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.30
- Dividend Yield
- —
Why Investors Own KAPA
- ✓High-growth profile — revenue up +39.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About KAIROS PHARMA LTD
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Bayer (XTRA:BAYN) Stock Still Looks Reasonable On New Prostate Cancer News
Bayer’s share price has climbed sharply over the past year, yet the valuation checks still suggest the stock screens as cheap on several measures. This raises the question of how much of the recent optimism is already reflected in the price. Bayer has returned 70.4% over the past year, which puts recent gains front and center for anyone assessing what is already priced in. The new collaboration with Kairos Pharma around XOFIGO in metastatic prostate cancer can support sentiment around...
Bayer (XTRA:BAYN) Stock Gets Two New Research Deals In Cancer And Heart Health
Bayer announced two new collaborations, one with Kairos Pharma on a prostate cancer therapy and another with Henry Ford Health on wider research across several diseases. The Kairos Pharma partnership focuses on combination treatments for metastatic prostate cancer. The alliance with Henry Ford Health covers cardiovascular, oncology, and women’s health research using advanced data and clinical technologies. Bayer, traded under XTRA:BAYN, is adding these research deals alongside a share price...
What's going on in today's after hours session
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares moved upwards by 24.0% to $1.71 during Wednesday's after-market session. The market value of their outstanding shares is at $135.0 million. Medpace Holdings
These stocks have an unusual volume in today's session
Unusual volume stocks in Wednesday's session
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
LOS ANGELES, July 22, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer’s XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) involving bone.